Immunomodulatory effects of deferoxamine and interferon gamma on human dental pulp stem cells

doi:10.12307/2022.137

Abstract

Abstract: BACKGROUND: Immune rejection is a great challenge for tissue or organ transplantation, and immunosuppressors often bring serious side effects to patients. The immunosuppressive effect of mesenchymal stem cells brings new hope for the treatment of immune rejection.
OBJECTIVE: To explore the effect of combined action of deferoxamine and interferon-γ on the immunomodulatory ability of human dental pulp stem cells.
METHODS: After pretreatment of human dental pulp stem cells with deferoxamine or interferon-γ or their combination, the proliferation of cells was detected with cell counting kit-8. The mRNA expression of some gene mRNA was examined by Q-PCR. The secretion of some immune regulatory factors was determined using ELISA. Thereafter, pretreated human dental pulp stem cells were co-cultured with mouse spleen lymphocytes, and then the proliferation of lymphocytes was detected by CFSE labeling by flow cytometry. After allogenic skin transplantation, mice were injected with PBS, human dental pulp stem cells or pretreated human dental pulp stem cells into tail vein immediately. The survival time of skin grafts was recorded. The pathology and immunohistochemistry of skin grafts were examined. Moreover, the proportion of Treg cells in spleen of transplanted mice was measured.
RESULTS AND CONCLUSION: (1) Deferoxamine or interferon-γ pretreatment inhibited the growth of human dental pulp stem cells, and the inhibition of deferoxamine was more significant than interferon-γ. (2) Pretreatment of deferoxamine combined with interferon-γ significantly increased the gene expression of vascular endothelial growth factor, interleukin 6, transforming growth factor β1, cyclooxygenase 2, human leukocyte antigen G, tumor necrosis factor A inducible protein 6 and interleukin 10, and promote secretion of interleukin 6, transforming growth factor β1 and prostaglandin E2. (3) The results of in vivo experiments confirmed that human dental pulp stem cells pretreated with deferoxamine combined with interferon-γ prolonged the survival time of mouse allograft skin, reduced the infiltration of CD4+T, CD8+T and macrophages at the grafted skin, and increased the proportion of Treg cells in the spleen of recipient mice. (4) It is concluded that deferoxamine combined with interferon-γ pretreatment enhanced the immunomodulatory effect of human dental pulp stem cells, and inhibited the immune rejection of skin allografts.

Key words: stem cells, human dental pulp stem cells, deferoxamine, interferon-γ, skin transplantation, immunomodulation, immune rejection

CLC Number:

Zhou Ying, Zhang Huan, Liao Song, Hu Fanqi, Yi Jing, Liu Yubin, Jin Jide. Immunomodulatory effects of deferoxamine and interferon gamma on human dental pulp stem cells[J]. Chinese Journal of Tissue Engineering Research, 2022, 26(7): 1012-1019.

Figures/Tables 9

References

[1] KITTLESON MM, KOBASHIGAWA JA. Cardiac Transplantation: Current Outcomes and Contemporary Controversies. JACC Heart Fail. 2017;5(12): 857-868.
[2] STEHLIK J, KOBASHIGAWA J, HUNT SA, et al. Honoring 50 Years of Clinical Heart Transplantation in Circulation: In-Depth State-of-the-Art Review. Circulation. 2018;137(1):71-87.
[3] YANG H, APRECIO RM, ZHOU X, et al. Therapeutic effect of TSG-6 engineered iPSC-derived MSCs on experimental periodontitis in rats: a pilot study. PLoS One. 2014;9(6):e100285.
[4] GRONTHOS S, MANKANI M, BRAHIM J, et al. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci U S A. 2000; 97(25):13625-13630.
[5] JI L, BAO L, GU Z, et al. Comparison of immunomodulatory properties of exosomes derived from bone marrow mesenchymal stem cells and dental pulp stem cells. Immunol Res. 2019;67(4-5):432-442.
[6] DUIJVESTEIN M, WILDENBERG ME, WELLING MM, et al. Pretreatment with interferon-γ enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells. 2011;29(10):1549-1558.
[7] OSES C, OLIVARES B, EZQUER M, et al. Preconditioning of adipose tissue-derived mesenchymal stem cells with deferoxamine increases the production of pro-angiogenic, neuroprotective and anti-inflammatory factors: Potential application in the treatment of diabetic neuropathy. PLoS One. 2017;12(5):e0178011.
[8] 孙卫民,王惠琴.细胞因子研究方法学[M].北京:人民卫生出版社, 1998:165-175.
[9] 赵洁. TGF-β对骨髓间充质干细胞免疫抑制作用的影响及机制研究[D].济南:山东大学,2019.
[10] HOLDEN P, NAIR LS. Deferoxamine: An Angiogenic and Antioxidant Molecule for Tissue Regeneration. Tissue Eng Part B Rev. 2019;25(6):461-470.
[11] BEEREPOOT LV, SHIMA DT, KUROKI M, et al. Up-regulation of vascular endothelial growth factor production by iron chelators. Cancer Res. 1996; 56(16):3747-3751.
[12] SHEN X, WAN C, RAMASWAMY G, et al. Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice. J Orthop Res. 2009;27(10):1298-1305.
[13] IKEDA Y, TAJIMA S, YOSHIDA S, et al. Deferoxamine promotes angiogenesis via the activation of vascular endothelial cell function. Atherosclerosis. 2011;215(2):339-347.
[14] CHEKANOV VS, NIKOLAYCHIK V, MATERNOWSKI MA, et al. Deferoxamine enhances neovascularization and recovery of ischemic skeletal muscle in an experimental sheep model. Ann Thorac Surg. 2003;75(1):184-189.
[15] HOFFBRAND AV, GANESHAGURU K, HOOTON JW, et al. Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br J Haematol. 1976;33(4):517-526.
[16] LEDERMAN HM, COHEN A, LEE JW, et al. Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood. 1984;64(3):748-753.
[17] HU K, OLSEN BR. The roles of vascular endothelial growth factor in bone repair and regeneration. Bone. 2016;91:30-38.
[18] PRICOLA KL, KUHN NZ, HALEEM-SMITH H, et al. Interleukin-6 maintains bone marrow-derived mesenchymal stem cell stemness by an ERK1/2-dependent mechanism. J Cell Biochem. 2009;108(3):577-588.
[19] HOOGDUIJN MJ, POPP F, VERBEEK R, et al. The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. Int Immunopharmacol. 2010;10(12):1496-1500.
[20] DE MIGUEL MP, FUENTES-JULIAN S, BLAZQUEZ-MARTINEZ A, et al. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med. 2012;12(5):574-591.
[21] YOU S, THIEBLEMONT N, ALYANAKIAN MA, et al. Transforming growth factor-beta and T-cell-mediated immunoregulation in the control of autoimmune diabetes. Immunol Rev. 2006;212:185-202.
[22] KEHRL JH. Transforming growth factor-beta: an important mediator of immunoregulation. Int J Cell Cloning. 1991;9(5):438-450.
[23] HUANG YH, ZOZULYA AL, WEIDENFELLER C, et al. T cell suppression by naturally occurring HLA-G-expressing regulatory CD4+ T cells is IL-10-dependent and reversible. J Leukoc Biol. 2009;86(2):273-281.
[24] GREENHOUGH A, SMARTT HJ, MOORE AE, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009;30(3):377-386.
[25] WILLIAMS CS, MANN M, DUBOIS RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999;18(55):7908-7916.
[26] SUBBARAMAIAH K, DANNENBERG AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci. 2003;24(2):96-102.
[27] NAKANISHI M, ROSENBERG DW. Multifaceted roles of PGE2 in inflammation and cancer. Semin Immunopathol. 2013;35(2):123-137.
[28] MOLNARFI N, BENKHOUCHA M, FUNAKOSHI H, et al. Hepatocyte growth factor: A regulator of inflammation and autoimmunity. Autoimmun Rev. 2015;14(4):293-303.
[29] SU J, CHEN X, HUANG Y, et al. Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species. Cell Death Differ. 2014;21(3):388-396.
[30] DAY AJ, MILNER CM. TSG-6: A multifunctional protein with anti-inflammatory and tissue-protective properties. Matrix Biol. 2019;78-79:60-83.
[31] ALEXANDER DZ, PEARSON TC, HENDRIX R, et al. Analysis of effector mechanisms in murine cardiac allograft rejection. Transpl Immunol. 1996; 4(1):46-48.
[32] YAMAMOTO N, EINAGA-NAITO K, KURIYAMA M, et al. Cellular basis of skin allograft rejection in mice: specific lysis of allogeneic skin components by non-T cells. Transplantation. 1998;65(6):818-825.
[33] GERSHON RK. A disquisition on suppressor T cells. Transplant Rev. 1975;26: 170-185.